TESARO (NASDAQ:TSRO)‘s stock had its “hold” rating reissued by stock analysts at Robert W. Baird in a report released on Friday, November 10th. They currently have a $120.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s target price would indicate a potential upside of 44.49% from the company’s current price.
A number of other analysts have also commented on TSRO. Janney Montgomery Scott reiterated a “neutral” rating on shares of TESARO in a research note on Friday, July 14th. ValuEngine lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub lowered shares of TESARO from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Credit Suisse Group set a $198.00 price target on shares of TESARO and gave the stock a “buy” rating in a research note on Wednesday, July 19th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target on shares of TESARO in a research note on Thursday, August 10th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. TESARO presently has an average rating of “Buy” and a consensus price target of $159.39.
Shares of TESARO (TSRO) traded up $2.37 during trading on Friday, reaching $83.05. 854,300 shares of the company’s stock traded hands, compared to its average volume of 1,025,782. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. TESARO has a twelve month low of $79.03 and a twelve month high of $192.94.
In other TESARO news, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Martin H. Jr. Huber sold 592 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the transaction, the senior vice president now owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,692 shares of company stock valued at $4,628,976. Company insiders own 34.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in TSRO. Janus Henderson Group PLC purchased a new position in shares of TESARO in the second quarter worth $100,301,000. PointState Capital LP purchased a new position in shares of TESARO in the second quarter worth $85,971,000. TimesSquare Capital Management LLC purchased a new position in shares of TESARO in the third quarter worth $33,911,000. Pictet Asset Management Ltd. lifted its holdings in shares of TESARO by 58.1% in the third quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock worth $81,450,000 after buying an additional 231,799 shares in the last quarter. Finally, Pioneer Investment Management Inc. lifted its holdings in shares of TESARO by 195.6% in the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after buying an additional 210,273 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “TESARO (TSRO) Given Hold Rating at Robert W. Baird” was originally published by BBNS and is the property of of BBNS. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/tesaro-inc-tsro-stock-rating-reaffirmed-by-robert-w-baird/1773859.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with our FREE daily email newsletter.